Unity Biotechnology found using ticker (UBX) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 12 and 4 calculating the average target price we see 6.86. Given that the stocks previous close was at 2.98 this indicates there is a potential upside of 130.2%. The 50 day moving average now sits at 3.23 while the 200 day moving average is 4.47. The company has a market cap of $162m. Find out more information at: http://www.unitybiotechnology.com
Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge and changed its name to Unity Biotechnology in January 2015. Unity Biotechnology was incorporated in 2009 and is headquartered in South San Francisco, California.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.